Sphingosine-1-phosphate signaling in IBD
The project will be a multi-site cohort study. The project is based on extensive and very solid preliminary studies. Substantial preliminary data have clearly demonstrated an important role for SPL and S1P in IBD, as well as implicating STAT3 and its downstream targets in promoting disease progression. S1P levels will be available for comparison in year two. Endpoints include plasma S1P, cytokines and molecular indicators of S1P signaling in intestinal samples of patients with IBD and controls matched for age and gender. Researchers will correlate S1P signaling with established markers of inflammation and clinical status. There are no treatment arms, use of placebo or comparison drug/device and randomization in this study.
Male and female patients (ages 1-25) receiving a colonoscopy for a medically indicated condition will be recruited in the pediatric IBD clinic.